Adalimumab

證據等級: L5

預測適應症: 10 個

Adalimumab: From Rheumatoid Arthritis to Rheumatoid Vasculitis

One-Sentence Summary

Adalimumab (Humira®) is a fully human anti-TNF-α monoclonal antibody globally approved for the treatment of rheumatoid arthritis and other chronic inflammatory diseases, with no current marketing authorisation recorded in the Danish regulatory database. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, with 5 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Rheumatoid arthritis (globally approved; no marketing authorisation currently recorded in Danish regulatory data)
Predicted New Indication	Rheumatoid Vasculitis
TxGNN Prediction Score	99.80%
Evidence Level	L3
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, adalimumab is a fully human IgG1 monoclonal antibody that targets tumour necrosis factor-alpha (TNF-α). It works by blocking both soluble and membrane-bound TNF-α from binding to its receptors (p55 and p75), thereby suppressing the NF-κB signalling pathway and reducing the downstream cascade of pro-inflammatory cytokines including IL-1β, IL-6, and IL-8. This core mechanism underlies its established use in conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease.

Rheumatoid vasculitis (RV) is one of the most severe extra-articular manifestations of long-standing, seropositive rheumatoid arthritis, typically affecting small and medium-sized blood vessels. Its pathogenesis shares the same central inflammatory driver as RA: immune complex deposition in vessel walls combined with TNF-α overexpression jointly drives vascular wall damage, endothelial cell activation, and complement cascade activation. Because adalimumab directly neutralises this key cytokine, the mechanistic basis for its application in RV is biologically coherent and follows directly from its established mode of action in RA.

A 2021 systematic review specifically addressing the role of biological agents in RV (PMID 33058033) documented the use of TNF inhibitors including adalimumab in this condition. A case report (PMID 25133007) described a patient with long-standing RA and digital vasculitis with necrotising fingertip ulcers who responded well to adalimumab after conventional therapy failed. Conversely, a case of acute pulmonary hypertension crisis following adalimumab dose reduction in established RV (PMID 30773522) simultaneously confirms the drug’s activity in this condition and highlights the serious clinical consequences of treatment interruption — reinforcing the need for careful dose management if adalimumab is used for RV.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02590562	N/A	Completed	808	Multi-centre cross-sectional study of biological DMARD treatment patterns (including adalimumab) in Chinese RA patients; provides real-world context on biologic use across the RA disease spectrum, indirectly relevant to RV management
NCT01579006	N/A	Completed	184	Non-interventional observational study of tocilizumab in RA patients with inadequate response to prior biologics including adalimumab; 6-month follow-up provides safety and effectiveness data in a population that may include patients with extra-articular manifestations such as RV
NCT05696106	N/A	Unknown	750,000	Large retrospective epidemiological study assessing the risk of incident immune-mediated inflammatory diseases (IMID) in patients treated with biologics; provides population-level context on inflammatory disease progression under biologic therapy
NCT07138898	Phase 2	Not yet recruiting	80	Evaluates perioperative immunosuppressant management in rheumatology patients undergoing elective shoulder arthroplasty; includes anti-TNF agents and provides safety data on treatment interruption in rheumatologic disease
NCT05111743	N/A	Completed	9,261	Retrospective real-world cohort of brolucizumab for neovascular AMD; low direct relevance to adalimumab in RV — likely matched by inflammatory or neovascular keyword overlap

Note: No direct randomised controlled trials specifically evaluating adalimumab for rheumatoid vasculitis were identified in the current search. All trials above are indirectly relevant. Evidence for this indication rests primarily on observational studies and case-level literature.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33058033	2021	Systematic Review	Clinical Rheumatology	PRISMA-compliant systematic review on biological agents (TNF inhibitors, rituximab, tocilizumab) in RV; confirms that biologics including adalimumab are being incorporated into the therapeutic armamentarium for this severe RA complication, with significant associated morbidity and mortality
34068884	2021	Narrative Review	Journal of Clinical Medicine	Comprehensive review of RA-associated episcleritis and scleritis, including the role of TNF-α inhibitors; relevant because ocular vasculitis overlaps with systemic RV pathogenesis
28123776	2017	Cohort	RMD Open	BSRBR-RA registry analysis characterising the drug-specific risk of vasculitis-like events (VLEs) in TNFi-treated RA patients compared with non-biological DMARD controls; provides risk quantification data essential for benefit-risk assessment
37699653	2024	Cohort	Annals of the Rheumatic Diseases	HLA-DRB1 and HLA-DQA1 alleles associated with immunogenicity to adalimumab in RA; pharmacogenomic data relevant to predicting adalimumab treatment durability in RV patients
36418100	2023	Case Series	Internal Medicine (Tokyo)	ANCA-associated nephritis developing during combined abatacept and adalimumab therapy in an RA patient; attenuated by tocilizumab; illustrates the complexity of autoimmune renal vasculitis during biologic therapy and the need for renal monitoring
25133007	2014	Case Report	Case Reports in Rheumatology	42-year-old female with 15-year RA history and digital vasculitis (necrotising fingertip ulcers); responded well to adalimumab — direct clinical evidence supporting adalimumab efficacy in RV
30773522	2019	Case Report	Internal Medicine (Tokyo)	Acute pulmonary hypertension crisis 8 months after adalimumab dose reduction in established RV; patient died despite steroid pulse therapy — critical safety signal emphasising the risks of treatment interruption
19482531	2009	Case Report	Nephrologie & Therapeutique	MPO-ANCA-positive extracapillary glomerulonephritis (necrotising vasculitis) developing during adalimumab therapy for RA; important safety signal for renal surveillance in RV patients receiving adalimumab
28719435	2018	Case Report	Am J Dermatopathology	Leukocytoclastic vasculitis with cutaneous perivascular hemophagocytosis in a patient receiving adalimumab for RA; highlights the paradoxical vasculitis phenomenon known to occur with TNF-α inhibitors
21385558	2011	Case Report	Clinical and Experimental Rheumatology	Successful treatment with anti-IL-6R antibody (tocilizumab) in multidrug-refractory, anti-TNF-resistant systemic RV; provides essential treatment sequencing context for patients who fail or cannot receive adalimumab

Denmark Market Information

According to available regulatory data, adalimumab currently has no recorded marketing authorisations with the Danish Medicines Agency (Lægemiddelstyrelsen). This is most likely a data collection gap rather than a genuine absence from the Danish market: adalimumab (Humira®) and multiple biosimilars (Imraldi®, Hyrimoz®, Amgevita®, Hadlima®, and others) hold EMA centralised marketing authorisations valid across all EU member states including Denmark, covering indications such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Crohn’s disease, and others.

For prescribing information applicable in Denmark, consult:

EMA Humira® EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/humira
Lægemiddelstyrelsen product database: https://produktresume.dk

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A 2021 systematic review provides direct evidence that biological agents including adalimumab are used in rheumatoid vasculitis, and the TNF-α inhibition mechanism is mechanistically well-aligned with RV pathogenesis; however, the complete absence of prospective RCTs specifically in RV, combined with the dual observation that adalimumab can both treat and paradoxically trigger vasculitic events, requires rigorous patient selection criteria, pre-treatment screening, and structured monitoring before wider clinical adoption.

To proceed, the following is needed:

Formal retrieval and review of the SmPC warnings and contraindications, including blackbox warnings (currently a blocking data gap)
Confirmation of current Danish/EU marketing authorisation status and approved indications via Lægemiddelstyrelsen and the EMA database
Completion of a detailed mechanism of action review from DrugBank (DB00051) or equivalent authoritative source
Design of a prospective registry or observational cohort study specifically evaluating adalimumab in rheumatoid vasculitis, given the current absence of RCT-level evidence for this specific indication
Pre-treatment screening protocol: latent tuberculosis testing (Mantoux/IGRA), hepatitis B serology, ANCA titres, urinalysis, and baseline renal function
Ongoing safety monitoring plan: renal function, ANCA titres, vasculitis disease activity index (e.g., Birmingham Vasculitis Activity Score), and injection site reactions
Review of drug-drug interaction profile, particularly for immunosuppressants commonly co-prescribed in RV (e.g., cyclophosphamide, azathioprine)

⚠️ Disclaimer: This report is generated for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application. All prescribing decisions must be made by qualified healthcare professionals in accordance with approved product labelling and applicable clinical guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.